Clareo Health | Evaluation of the Efficacy and Safety of Treatments for Patients Hospitalized for COVID-19 Infection Without Signs of Acute Respiratory Failure, in Tunisia
Evaluation of the Efficacy and Safety of Treatments for Patients Hospitalized for COVID-19 Infection Without Signs of Acute Respiratory Failure, in Tunisia
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Abderrahmane Mami Hospital
With
Eshmoun Clinical Research Center
Datametrix
Arm 1:
* Hydroxychloroquine (HCQ): 600 mg on the 1st day as a starting dose then 200 mg \* 2 /D for 9 days
* Azithromycin: 500 mg (1st day) then 250 mg / D for 4 days
* Usual standard treatment
Arm 2:
* HCQ: 600 mg on the 1st day as a starting dose then 200 mg \* 2 / D for 9 days
* Azithromycin: 500 mg (1st day) then 250 mg / D for 4 days
* Zinc: 220 mg per day for 10 days
* Usual standard treatment
Arm 3:
* Azithromycin: 500 mg (1st day) then 250 mg / D for 4 days
* Doxycycline: 200 mg per day for 10 days.
* Usual standard treatment
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Confirmed patient COVID19 positive with clinical signs of acute lower respiratory infection with signs of pneumonia or bronchitis: fever and / or cough and / or difficulty breathing in the absence of acute respiratory failure (PaO2\> 60 mmHg) with Plus or less :
* Chills
* Asthenia, fatigability
* Headache
* Arthromas myalgia
* Dry throat
* Rhinorrhea
* An anosmia
* chest pain
* Diarrhea
* Nausea and vomiting
* Absence of rhythm disturbance (Qt interval \<500ms)
* Patients hospitalized in the medical service
* 18 years old \<Age \<80 years old
* Having given written consent for their participation in the study
You may not be if
Allergy to macrolides, local anesthetics such as lidocaine or amide type and betalactamines
